Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,000 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the sale, the general counsel now owns 133,730 shares of the company's stock, valued at $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apellis Pharmaceuticals Trading Down 0.0%

NASDAQ:APLS traded down $0.01 on Wednesday, reaching $17.75. The company's stock had a trading volume of 161,317 shares, compared to its average volume of 2,332,299. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $42.47. The stock has a 50 day moving average price of $18.27 and a 200 day moving average price of $24.98. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -9.96 and a beta of 0.68. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. During the same quarter last year, the firm posted ($0.54) earnings per share. The firm's quarterly revenue was down 3.2% on a year-over-year basis. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its position in Apellis Pharmaceuticals by 9.4% in the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after purchasing an additional 1,864 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Apellis Pharmaceuticals by 2.6% in the fourth quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company's stock valued at $28,170,000 after buying an additional 22,507 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Apellis Pharmaceuticals by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company's stock valued at $6,793,000 after buying an additional 21,822 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Apellis Pharmaceuticals by 140.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 33,594 shares of the company's stock worth $1,072,000 after acquiring an additional 19,641 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in Apellis Pharmaceuticals by 44.1% during the 4th quarter. Nuveen Asset Management LLC now owns 491,107 shares of the company's stock worth $15,671,000 after acquiring an additional 150,384 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on APLS. Citigroup dropped their price target on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Wedbush cut their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Bank of America downgraded shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Finally, Royal Bank Of Canada lowered their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a report on Thursday, May 8th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $40.05.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.